Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1 Paris, April 28, 2022 Q1 2022 sales growth of 8.6% at CER driven by Dupixent® and CHC Specialty Care grew 17.8% driven by Dupixent® (€1,614 million, +45.7%) Vaccines were up 6.8% reflecting strong […]